Study summary · 2022 · Evidence review
COPD home monitoring: uncertain clinical benefit
COPD monitoring did not consistently improve quality of life or utilization; low-certainty evidence leaves important uncertainty.
Summary by Vironix Health · Source review: November 11, 2026
How we select and interpret evidence
Original publication
Fernanda Inagaki Nagase; Tania Stafinski; Melita Avdagovska; Michael K. Stickland; Evelyn Melita Etruw; Devidas Menon
University of Alberta; Alberta Health Services; Covenant Health, Canada
BMC Health Services Research · Online: · Issue: 2022
Journal version of record. · Full text consulted.
What was studied
- Design
- Evidence review
- Population
- People with COPD
- Sample
- 19 studies: 17 randomized trials and 2 comparative observational studies; 3,144 participants
- Intervention
- Home transmission of symptoms and measurements, with differing feedback pathways
- Comparator
- Usual care or monitoring without provider feedback
- Follow-up
- Monitoring periods of 1–12 months
- Study/data period
- Included studies conducted in 2006–2018
- Review search cutoff
- 2020-03-13
- Setting
- Multiple countries
Methods
Narrative review with limited pooling, risk-of-bias assessment and GRADE. Designs and monitoring technologies differed.
Findings
Quality of life showed no clear between-group improvement. Seven of nine dedicated-device studies reported similar COPD hospitalization results; two favored monitoring. One study assessed adverse events and eight assessed mortality, without clear group differences.
Limitations
Evidence certainty was low or very low. Short follow-up, heterogeneous interventions and incomplete reporting limit inference. Sparse safety data do not establish safety equivalence.
What this means for care delivery
Do not transfer heart-failure or hypertension benefits to COPD. Provider feedback is promising, but its independent effect is not established across programs.